Skip to main content

Table 3 Trial construct 2—disease modification trial. Power to detect an expected 1.85-point difference in ADAS-cog change in the planned sample (n = 280)

From: Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

Trial modification Linear mixed effects model: categorical time Linear mixed effects model: continuous time Student’s t test Original t test (for reference)
Scenario 1 .42 .40 .19 .82
Scenario 2 .71 .67 .56 .82
Scenario 3 .75 .71 .64 .82
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193